Aerie Pharmaceuticals Stock Forecast, Price & News

Aerie Pharmaceuticals' stock was trading at $14.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AERI shares have decreased by 14.0% and is now trading at $12.52.
View which stocks have been most impacted by COVID-19.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aerie Pharmaceuticals or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Aerie Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aerie Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Aerie Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for Aerie Pharmaceuticals.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.81) by $0.16. Aerie Pharmaceuticals had a negative net margin of 231.05% and a negative return on equity of 135.57%.
View Aerie Pharmaceuticals' earnings history.

12 analysts have issued twelve-month target prices for Aerie Pharmaceuticals' shares. Their forecasts range from $9.00 to $40.00. On average, they expect Aerie Pharmaceuticals' stock price to reach $26.45 in the next twelve months. This suggests a possible upside of 111.3% from the stock's current price.
View analysts' price targets for Aerie Pharmaceuticals.

Aerie Pharmaceuticals saw a decrease in short interest in October. As of October 30th, there was short interest totaling 6,440,000 shares, a decrease of 17.0% from the October 15th total of 7,760,000 shares. Based on an average daily volume of 738,700 shares, the short-interest ratio is currently 8.7 days. Currently, 14.3% of the company's shares are short sold.
View Aerie Pharmaceuticals' Short Interest.

Some companies that are related to Aerie Pharmaceuticals include Replimune Group (REPL), AlloVir (ALVR), Sorrento Therapeutics (SRNE), Kymera Therapeutics (KYMR), NanoString Technologies (NSTG), Editas Medicine (EDIT), Atara Biotherapeutics (ATRA), Vaxcyte (PCVX), Forma Therapeutics (FMTX), Mesoblast (MESO), Bavarian Nordic A/S (BVNRY), Scholar Rock (SRRK), C4 Therapeutics (CCCC), Cortexyme (CRTX) and Translate Bio (TBIO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Canopy Growth (CGC), Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Aerie Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include C WorldWide Group Holding A S (3.13%), William Blair Investment Management LLC (3.05%), Levin Capital Strategies L.P. (2.88%), State Street Corp (2.16%), Rhenman & Partners Asset Management AB (1.83%) and Pinnacle Associates Ltd. (1.13%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino and Vicente Anido Jr.
View institutional ownership trends for Aerie Pharmaceuticals.

AERI stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Levin Capital Strategies L.P., Tarsadia Capital LLC, State Street Corp, Sei Investments Co., Cubist Systematic Strategies LLC, CWM LLC, and Pinnacle Associates Ltd.. Company insiders that have sold Aerie Pharmaceuticals company stock in the last year include Casey C Kopczynski, and Gerald D Cagle.
View insider buying and selling activity for Aerie Pharmaceuticals.

AERI stock was bought by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Rhenman & Partners Asset Management AB, Granite Investment Partners LLC, Voloridge Investment Management LLC, Worth Venture Partners LLC, Aperio Group LLC, William Blair Investment Management LLC, and Envestnet Asset Management Inc.. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Richard J Rubino, and Vicente Anido Jr.
View insider buying and selling activity for Aerie Pharmaceuticals.

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AERI stock can currently be purchased for approximately $12.52.

Aerie Pharmaceuticals has a market capitalization of $586.12 million and generates $69.89 million in revenue each year. The company earns $-199,580,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Aerie Pharmaceuticals employs 380 workers across the globe.

The official website for Aerie Pharmaceuticals is www.aeriepharma.com.

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]